Premium
5‐fluorouracil given once weekly: Comparison of intravenous and oral administration
Author(s) -
Bateman Joseph R.,
Pugh Reginald P.,
Cassidy Frank R.,
Marshall G. June,
Irwin Lowell E.
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(1971)28:4<907::aid-cncr2820280414>3.0.co;2-9
Subject(s) - medicine , fluorouracil , toxicity , group b , oral administration , body weight , gastroenterology , group a , cumulative dose , complete response , adenocarcinoma , surgery , cancer , chemotherapy
One hundred seven patients with disseminated adenocarcinoma were randomized to receive 5‐Fluorouracil (5‐FU) by vein, Group A (52 patients), or by mouth, Group B (55 patients). Dosage for both groups was 15 mg/kg body weight given once weekly. Clinically useful response rate was 21% for Group A (IV) and 40% for Group B (oral). Duration of response and mean cumulative dose to beginning response were comparable in both groups. Slight differences were observed in toxicities in the 2 groups. G.I. toxicity was more frequent in Group B (oral) and hematologic toxicity was more common in Group A (IV).